Phenoxy-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine-dioxide compounds (I) and their enantiomers and diastereoisomers, and addition salts with an acid or a base, are new. Phenoxy-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine-dioxide compounds of formula (I) and their enantiomers and diastereoisomers, and addition salts with an acid or a base, are new. R1 = H, CN, 1-6C alkoxycarbonyl group, 1-6C alkylsulfonylamino1-6C alkyl group or N-hydroxy carboximidamide group, where the heterocyclic group is a 5-membered monocyclic aryl group containing 1-4 heteroatoms of N, O or S, the heterocyclic group is optionally substituted by one or more 1-6C alkyl or polyhalo-1-6C-alkyl group. Independent claims are included for: (1) the preparation of (I) and (2) 3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine-1,1-dioxide compound of formula (V). Hal = halo such as fluorine, chlorine or bromine. [Image] [Image] ACTIVITY : Nootropic Tranquilizer Antidepressant Neuroprotective Antiparkinsonian Cerebroprotective Anticonvulsant Antialcoholic Neuroleptic Vasotropic. MECHANISM OF ACTION : Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor modulator. Tests details are described but no results given.본 발명은 하기 화학식 (Ⅰ)의 화합물 및 이의 AMPA 수용체 조절제로서의 용도에 관한 것이다:상기 식에서, R1은 수소 원자, 또는 헤테로사이클릭, 시아노, 알콕시카르보닐, 알킬설포닐아미노알킬 또는 N-하이드록시카르복시미드아미드 기를 나타낸다.
